Mucin-1-antibody-conjugated mesoporous silica nanoparticles for selective breast cancer detection in a mucin-1 transgenic murine mouse model

Journal of Biomedical Nanotechnology

Volumn 12, Issue 12, 2016, Pages 2172-2184

  Dréau, Didier ^a,b   Moore, Laura Jeffords ^a   Alvarez Berrios, Merlis P ^a,c   Tarannum, Mubin ^a,b   Mukherjee, Pinku ^a,b   Vivero Escoto, Juan L ^a,b  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^b NONE   (United States)

^c University of North Carolina at Charlotte   (United States)

Author keywords

Breast Cancer; Diagnosis; Mesoporous Silica Nanoparticles; Mucin 1; Transgenic Mouse Model

Indexed keywords

ANTIBODIES; CHEMICAL DETECTION; DIAGNOSIS; DISEASES; INFRARED DEVICES; MAMMALS; MESOPOROUS MATERIALS; NANOPARTICLES; NANOPROBES; SILICA; TUMORS;

BREAST CANCER; BREAST CANCER DETECTION; IN-VIVO EXPERIMENTS; MESOPOROUS SILICA NANOPARTICLES; MUCIN-1; NANO PARTICULATES; TRANSGENIC MICE; TRANSMEMBRANE GLYCOPROTEINS;

MEDICAL IMAGING;

CARBOXYLIC ACID; CONTRAST MEDIUM; FLUORESCEIN ISOTHIOCYANATE; FLUORESCEIN ISOTHIOCYANATE MESOPOROUS SILICA NANOPARTICLE MONOCLONAL ANTIBODY TAB 004 CONJUGATE; MACROGOL; MUCIN 1; NIR 797 CYANINE DYE MESOPOROUS SILICA NANOPARTICLE MONOCLONAL ANTIBODY TAB 004 CONJUGATE; SILANE DERIVATIVE; UNCLASSIFIED DRUG; NANOPARTICLE; SILICON DIOXIDE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN RECOGNITION; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CYTOTOXICITY; DRUG TARGETING; EPITHELIUM CELL; FEMALE; FLUORESCENCE IMAGING; IMAGING SOFTWARE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; KIDNEY; LIVER; MOUSE; NANOFABRICATION; NANOPROBE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN; ANIMAL; BREAST NEOPLASMS; C57BL MOUSE; DISEASE MODEL; HUMAN; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; TRANSGENIC MOUSE;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCIN-1; NANOPARTICLES; SILICON DIOXIDE;

EID: 84994251951     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2016.2318     Document Type: Article

References (60)

1. S. Nath and P. Mukherjee, MUC1: A multifaceted oncoprotein with a key role in cancer progression. Trends Mol. Med. 20, 332 (2014).
2. A. Moore, Z. Medarova, A. Potthast, and G. Dai, In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res. 64, 1821 (2004).
3. L. Cai, Z.-Z. Chen, M.-Y. Chen, H.-W. Tang, and D.-W. Pang, MUC- 1 aptamer-conjugated dye-doped silica nanoparticles for MCF-7 cells detection. Biomaterials 34, 371 (2013).
4. L. J. Moore, L. D. Roy, R. Zhou, P. Grover, S.-T. Wu, J. M. Curry, L. M. Dillon, P. M. Puri, M. Yazdanifar, R. Puri, P. Mukherjee, and D. Dreau, Antibody-guided in vivo imaging for early detection of mammary gland tumors. Trans. Oncol. 9, 295 (2016).
5. S. B. Ho, G. A. Niehans, C. Lyftogt, P. S. Yan, D. L. Charwitz, E. T. Gum, R. Dahiya, and Y. S. Kim, Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 53, 641 (1993).
6. D. Chen, J. Xia, Y. Tanaka, H. Chen, S. Koido, O. Wernet, P. Mukherjee, S. J. Gendler, D. Kufe, and J. Gong, Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 109, 300 (2003).
7. J. M. Curry, K. J. Thompson, S. G. Rao, D. M. Besmer, A. M. Murphy, V. Z. Grdzelishvili, W. A. Ahrens, I. H. McKillop, D. Sindram, D. A. Iannitti, J. B. Martinie, and P. Mukherjee, The use of a novel MUC1 antibody to identify cancer stem cells and circulating MUC1 in mice and patients with pancreatic cancer. J. Surg. Oncol. 107, 713 (2013).
8. P. Mukherjee, C. S. Madsen, A. R. Ginardi, T. L. Tinder, F. Jacobs, J. Parker, B. Agrawal, B. M. Longenecker, and S. J. Gendler, Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer. J. Immunother. 26, 47 (2003).
9. J. E. Green, and T. Hudson, The promise of genetically engineered mice for cancer prevention studies. Nat. Rev. Cancer. 5, 184 (2005).
10. H. HogenEsch, and A. Y. Nikitin, Challenges in pre-clinical testing of anti-cancer drugs in cell culture and in animal models. J. Controlled Release 164, 183 (2012).
11. F. Jia, X. Liu, L. Li, S. Mallapragada, B. Narasimhan, and Q. Wang, Multifunctional nanoparticles for targeted delivery of immune activating and cancer therapeutic agents. J. Controlled Release 172, 1020 (2013).
12. Y. Yang, S. Wang, Y. Wang, X. Wang, Q. Wang, and M. Chen, Advances in self-assembled chitosan nanomaterials for drug delivery. Biotechnol. Adv. 32, 1301 (2014).
13. H. Peng, X. Liu, G. Wang, M. Li, K. M. Bratlie, E. Cochran, and Q. Wang, Polymeric multifunctional nanomaterials for theranostics. J. Mater. Chem. B. 3, 6856 (2015).
14. F. Song, X. Li, Q. Wang, L. Liao, and C. Zhang, Nanocomposite hydrogels and their applications in drug delivery and tissue engineering. J. Biomed. Nanotechnol. 11, 40 (2015).
15. T. Thambi, and J. H. Park, Recent advances in shell-sheddable nanoparticles for cancer therapy. J. Biomed. Nanotechnol. 10, 1841 (2014).
16. M. H. Li, H. Yu, T. F. Wang, N. D. Chang, J. Q. Zhang, D. Du, M. F. Liu, S. L. Sun, R. Wang, H. Q. Tao, S. L. Geng, Z. Y. Shen, Q. Wang, and H. S. Peng, Tamoxifen embedded in lipid bilayer improves the oncotarget of liposomal daunorubicin in vivo. J. Mater. Chem. B. 2, 1619 (2014).
17. H. Peng, C. Wang, X. Xu, C. Yu, and Q. Wang, An intestinal Trojan horse for gene delivery. Nanoscale. 7, 4354 (2015).
18. J. Cao, R. Wang, N. Gao, M. Li, X. Tian, W. Yang, Y. Ruan, C. Zhou, G. Wang, X. Liu, S. Tang, Y. Yu, Y. Liu, G. Sun, H. Peng, and Q. Wang, A7RC peptide modified paclitaxel liposomes dually target breast cancer. Biomater. Sci. 3, 1545 (2015).
19. D. Gozuacik, H. F. Yagci-Acar, Y. Akkoc, A. Kosar, A. I. Dogan- Ekici, and S. Ekici, Anticancer use of nanoparticles as nucleic acid carriers. J. Biomed. Nanotechnol. 10, 1751 (2014).
20. M. Liu, M. Li, S. Sun, B. Li, D. Du, J. Sun, F. Cao, H. Li, F. Jia, T. Wang, N. Chang, H. Yu, Q. Wang, and H. Peng, The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials. 35, 3697 (2014).
21. D. Du, N. Chang, S. Sun, M. Li, H. Yu, M. Liu, X. Liu, G. Wang, H. Li, X. Liu, S. Geng, Q. Wang, and H. Peng, The role of glucose transporters in the distribution of p-aminophenyl-α- D-mannopyranoside modified liposomes within mice brain. J. Controlled Release 182, 99 (2014).
22. M. Li, H. Deng, H. Peng, and Q. Wang, Functional nanoparticles in targeting glioma diagnosis and therapies. J. Nanosci. Nanotechnol. 14, 415 (2014).
23. M. A. Hahn, A. K. Singh, P. Sharma, S. C. Brown, and B. M. Moudgil, Nanoparticles as contrast agents for in-vivo bioimaging: Current status and future perspectives. Anal. Bioanal. Chem. 399, 3 (2011).
24. H. S. Choi, and J. V. Frangioni, Nanoparticles for biomedical imaging: Fundamentals of clinical translation. Mol. Imaging 9, 2910 (2010).
25. M. Montalti, L. Prodi, E. Rampazzo, and N. Zaccheroni, Dyedoped silica nanoparticles as luminescent organized systems for nanomedicine. Chem. Soc. Rev. 43, 4243 (2014).
26. B. P. Danysh, P. E. Constantinou, E. Y. Lukianova-Hleb, D. O. Lapotko, and D. D. Carson, The MUC1 ectodomain: A novel and efficient target for gold nanoparticle clustering and vapor nanobubble generation. Theranostics. 2, 777 (2012).
27. Z. Ghasemi, R. Dinarvand, F. Mottaghitalab, M. Esfandyari-Manesh, E. Sayari, and F. Atyabi, Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. Carbohydr. Polym. 121, 190 (2015).
28. M. Hasegawa, R. K. Sinha, M. Kumar, M. Alam, L. Yin, D. Raina, A. Kharbanda, G. Panchamoorthy, D. Gupta, H. Singh, S. Kharbanda, and D. Kufe, Intracellular targeting of the oncogenic MUC1-C protein with a novel GO-203 nanoparticle formulation. Clin. Cancer Res. 21, 2338 (2015).
29. H. Jo, J. Her, and C. Ban, Dual aptamer-functionalized silica nanoparticles for the highly sensitive detection of breast cancer. Biosens. Bioelectron. 71, 129 (2015).
30. H. Kouchakzadeh, S. A. Shojaosadati, J. Mohammadnejad, M. Paknejad, and M. J. Rasaee, Attachment of an anti-MUC1 monoclonal antibody to 5-FU loaded BSA nanoparticles for active targeting of breast cancer cells. Hum. Antibodies 21, 49 (2012).
31. E. Sayari, M. Dinarvand, M. Amini, M. Azhdarzadeh, E. Mollarazi, Z. Ghasemi, and F. Atyabi, MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery. Int. J. Pharm. 473, 304 (2014).
32. C. Yu, Y. Hu, J. Duan, W. Yuan, C. Wang, H. Xu, and X.-D. Yang, Novel aptamer-nanoparticle bioconjugates enhances delivery of anticancer drug to MUC1-positive cancer cells in vitro. PLoS One 6, e24077 (2011).
33. S. Shanehsazzadeh, C. Gruettner, A. Lahooti, M. Mahmoudi, B. J. Allen, M. Ghavami, F. J. Daha, and M. A. Oghabian, Monoclonal antibody conjugated magnetic nanoparticles could target MUC-1- positive cells in vitro but not in vivo. Contrast Media Mol. Imaging 10, 225 (2015).
34. J. L. Vivero-Escoto, R. C. Huxford-Phillips, and W. Lin, Silicabased nanoprobes for biomedical imaging and theranostic applications. Chem. Soc. Rev. 41, 2673 (2012).
35. C. Caltagirone, A. Bettoschi, A. Garau, and R. Montis, Silica-based nanoparticles: A versatile tool for the development of efficient imaging agents. Chem. Soc. Rev. 44, 4645 (2015).
36. Q. He and J. Shi, Mesoporous silica nanoparticle based nano drug delivery systems: Synthesis, controlled drug release and delivery, pharmacokinetics and biocompatibility. J. Mater. Chem. 21, 5845 (2011).
37. Q. He, and J. Shi, MSN anti-cancer nanomedicines: Chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv. Mater. 26, 391 (2014).
38. J. L. Vivero-Escoto, I. I. Slowing, B. G. Trewyn, and V. S. Y. Lin, Mesoporous Silica Nanoparticles for Intracellular Controlled Drug Delivery. Small. 6, 1952 (2010).
39. C.-H. Lee, S.-H. Cheng, Y.-J. Wang, Y.-C. Chen, N.-T. Chen, J. Souris, C.-T. Chen, C.-Y. Mou, C.-S. Yang, and L.-W. Lo, Nearinfrared mesoporous silica nanoparticles for optical imaging: Characterization and in vivo biodistribution. Adv. Funct. Mater. 19, 215 (2009).
40. X. Hu, M. Wang, F. Miao, J. Ma, H. Shen, and N. Jia, Regulation of multifunctional mesoporous core-shell nanoparticles with luminescence and magnetic properties for biomedical applications. J. Mater. Chem. B. 2, 2265 (2014).
41. S. Gandhi, K. Thandavan, B.-J. Kwon, H.-J.Woo, S. S. Yi, H. S. Lee, J. H. Jeong, K. Jang, and D. S. Shin, Mesoporous silica. A highly promising and compatible candidate for optical and biomedical applications. RSC Adv. 4, 5953 (2014).
42. S. Palantavida, R. Tang, G. P. Sudlow, W. J. Akers, S. Achilefu, and I. Sokolov, Ultrabright NIR fluorescent mesoporous silica nanoparticles. J. Mater. Chem. B 2, 3107 (2014).
43. L. Tao, C. Song, Y. Sun, X. Li, Y. Li, B. Jin, Z. Zhang, and K. Yang, A fluorescent and chemiluminescent difunctional mesoporous silica nanoparticle as a label for the ultrasensitive detection of cancer cells. Anal. Chim. Acta 761, 194 (2013).
44. K. Ma, H. Sai, and U. Wiesner, Ultrasmall sub-10 nm near-infrared fluorescent mesoporous silica nanoparticles. J. Am. Chem. Soc. 134, 13180 (2012).
45. J. S. Souris, C.-H. Lee, S.-H. Cheng, C.-T. Chen, C.-S. Yang, J.-A. A. Ho, C.-Y. Mou, and L.-W. Lo, Surface charge-mediated rapid hepatobiliary excretion of mesoporous silica nanoparticles. Biomaterials 31, 5564 (2010).
46. F. Chen, T. R. Nayak, S. Goel, H. F. Valdovinos, H. Hong, C. P. Theuer, T. E. Barnhart, and W. Cai, In Vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles. Mol. Pharmaceutics 11, 4007 (2014).
47. F. Chen, H. Hong, S. Goel, S. A. Graves, H. Orbay, E. B. Ehlerding, S. Shi, C. P. Theuer, R. J. Nickles, and W. Cai, In Vivo tumor vasculature targeting of CuS@MSN based theranostic nanomedicine. ACS Nano. 9, 3926 (2015).
48. Z. Liu, P. Rong, L. Yu, X. Zhang, C. Yang, F. Guo, Y. Zhao, K. Zhou, W. Wang, and W. Zeng, Dual-modality noninvasive mapping of sentinel lymph node by photoacoustic and near-infrared fluorescent imaging using dye-loaded mesoporous silica nanoparticles. Mol. Pharmaceutics 12, 3119 (2015).
49. W. A. Walker, M. Tarannum, and J. L. Vivero-Escoto, Cellular endocytosis and trafficking of cholera toxin B-modified mesoporous silica nanoparticles. J. Mater. Chem. B 4, 1254 (2016).
50. L. D. Roy, M. Sahraei, D. B. Subramani, D. Besmer, S. Nath, T. L. Tinder, E. Bajaj, K. Shanmugam, Y. Y. Lee, S. I. L. Hwang, S. J. Gendler, and P. Mukherjee, MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 30, 1449 (2011).
51. T. Yardeni, M. Eckhaus, H. D. Morris, M. Huizing, and S. Hoogstraten-Miller, Retro-orbital injections in mice. Lab. Anim. 40, 155 (2011).
52. A. Schoch, T. Emrich, I. S. Thorey, J. Engert, and G. Winter, Comparison of the lateral tail vein and the retro-orbital venous sinus routes of antibody administration in pharmacokinetic studies. Lab. Anim. 43, 95 (2014).
53. J. E. Price, R. F. Barth, C. W. Johnson, and A. E. Staubus, Injection of cells and monoclonal antibodies into mice: Comparison of tail vein and retroorbital routes. Proc. Soc. Exp. Biol. Med. 177, 347 (1984).
54. C. D. Steel, A. L. Stephens, S. M. Hahto, S. J. Singletary, and R. P. Ciavarra, Comparison of the lateral tail vein and the retro-orbital venous sinus as routes of intravenous drug delivery in a transgenic mouse model. Lab. Anim. 37, 26 (2008).
55. Z.-A. Qiao, L. Zhang, M. Guo, Y. Liu, and Q. Huo, Synthesis of Mesoporous Silica Nanoparticles via Controlled Hydrolysis and Condensation of Silicon Alkoxide. Chem. Mater. 21, 3823 (2009).
56. P. A. Beales, N. Geerts, K. K. Inampudi, H. Shigematsu, C. J. Wilson, and T. K. Vanderlick, Reversible assembly of stacked membrane nanodiscs with reduced dimensionality and variable periodicity. J. Am. Chem. Soc. 135, 3335 (2013).
57. M. Nasr, M. K. Ghorab, and A. Abdelazem, In vitro and in vivo evaluation of cubosomes containing 5-fluorouracil for liver targeting. Acta Pharmaceutica Sinica B 5, 79 (2015).
58. N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O. C. Farokhzad, Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv. Drug Delivery Rev. 66, 2 (2014).
59. M. J. Stechman, B. N. Ahmad, N. Y. Loh, A. A. C. Reed, M. Stewart, S. Wells, T. Hough, L. Bentley, R. D. Cox, S. D. M. Brown, and R. V. Thakker, Establishing normal plasma and 24-hour urinary biochemistry ranges in C3H, BALB/c and C57BL/6J mice following acclimatization in metabolic cages. Lab. Anim. 44, 218 (2010).
60. J. Rodriguez, and I. Fernandez, Clinical biochemistry parameters in C57BL/6J mice after blood collection from the submandibular vein and retroorbital plexus. Reply. J. Am. Assoc. Lab. Anim. Sci. 49, 400 (2010).